Gabrielle Union Transformation Timeline: Public Photos, Public Statements, and the Medical Context

By
Published Updated Last reviewed
Hormone therapy clinical care image for Gabrielle Union Transformation Timeline: Public Photos, Public Statements, and the Medical Context

At a glance

  • What is confirmed: Union has publicly confirmed undergoing IVF (including hormone stimulation protocols), receiving a diagnosis of adenomyosis, experiencing "eight or nine" failed IVF transfers, using a gestational surrogate for her daughter Kaavia, and discussing perimenopause symptoms openly.
  • What is speculated: Specific drug names, dosages, and any current menopausal hormone therapy (MHT) regimen have not been publicly disclosed.
  • Drug family: Women's HRT, fertility hormones (gonadotropins, estrogen/progesterone supplementation), perimenopause management.
  • Why it matters: Union's candor about adenomyosis and IVF failure rates gives clinical context to conditions that affect millions of women but remain undertreated and underdiagnosed.

The Public Record: A Chronological Map

2017: The Adenomyosis Disclosure

In her 2017 memoir We're Going to Need More Wine, Gabrielle Union described years of fertility struggles and confirmed she had been diagnosed with adenomyosis, a condition in which endometrial-like tissue grows into the muscular wall of the uterus. She wrote about multiple miscarriages and what she called "the most soul-crushing, confidence-sapping" experience of failed IVF cycles.

Adenomyosis affects an estimated 20% to 35% of women, though prevalence numbers vary widely because definitive diagnosis historically required hysterectomy. Magnetic resonance imaging has improved non-invasive detection significantly. The condition is associated with heavy menstrual bleeding, chronic pelvic pain, and reduced IVF implantation rates. A 2017 meta-analysis published in Human Reproduction Update found that women with adenomyosis undergoing IVF had a clinical pregnancy rate roughly 28% lower than controls.

2018: IVF Protocols and the Surrogacy Decision

Union and her husband Dwyane Wade welcomed daughter Kaavia James via gestational surrogate in November 2018. In interviews surrounding the birth, Union confirmed she had undergone "eight or nine" IVF attempts before turning to surrogacy. Each of those cycles would have involved a standard controlled ovarian hyperstimulation (COH) protocol.

A typical COH protocol includes gonadotropin-releasing hormone (GnRH) agonists or antagonists to suppress premature ovulation, follicle-stimulating hormone (FSH) injections to stimulate multiple follicle development, and a trigger shot of human chorionic gonadotropin (hCG) or a GnRH agonist to induce final oocyte maturation. Estradiol levels during stimulation commonly reach 1,000 to 4,000 pg/mL, far above the normal follicular-phase range of 20 to 160 pg/mL. Progesterone supplementation follows embryo transfer to support the luteal phase. The American Society for Reproductive Medicine notes that each IVF cycle carries approximately a 40% to 50% live birth rate for women under 35, with success rates declining with age and underlying uterine pathology.

The HealthRX Medical Team's clinical note: Eight or nine IVF cycles represents substantial cumulative hormonal exposure. Each stimulation cycle floods the body with supraphysiologic estrogen levels for 10 to 14 days, followed by progesterone support lasting weeks. While large registry studies, including a 2019 analysis in the BMJ covering over 250,000 women, have not established a clear link between IVF hormone exposure and long-term breast cancer risk, the physical and emotional toll of repeated cycles is well documented. Union's willingness to share the number of failed attempts provides a realistic counter to media narratives that treat IVF as a reliable backup plan. The cumulative live birth rate after multiple cycles is higher than per-cycle rates suggest, but each additional round carries diminishing returns and increasing emotional burden, a point Union herself has emphasized.

2019 to 2021: Perimenopause Goes Public

In a series of interviews and social media posts, Union began discussing perimenopause symptoms she experienced in her mid-to-late 40s. She described hot flashes, sleep disruption, and mood changes. She credited open conversations with her doctors for helping her recognize the transition.

Perimenopause typically begins in the mid-40s, though onset can range from the late 30s to early 50s. It is defined by irregular menstrual cycles and fluctuating estradiol and FSH levels, and lasts on average four to eight years before final menstrual period. The 2022 Menopause Society position statement reaffirmed that hormone therapy remains the most effective treatment for vasomotor symptoms (hot flashes, night sweats), with systemic estrogen reducing hot flash frequency by approximately 75%. For women with a uterus, progestogen must accompany estrogen to protect against endometrial hyperplasia.

Union has not publicly confirmed whether she uses menopausal hormone therapy. Any claims that she takes or does not take specific HRT medications remain speculative.

2022 to Present: Continued Advocacy

Union has continued to use her platform to discuss reproductive and hormonal health. She spoke at length during press for the film The Perfect Find (2023) about normalizing perimenopause conversations in workplaces and relationships. She has also been vocal about the racial disparities in reproductive medicine, noting that Black women face higher rates of fibroids, adenomyosis, and poorer IVF outcomes compared to white women, a pattern confirmed across multiple large cohort studies.

A 2021 study in Fertility and Sterility found that Black women had a 10% lower live birth rate per IVF cycle compared to white women even after adjusting for age, BMI, and diagnosis. These disparities likely reflect a combination of biological factors (such as higher fibroid prevalence), socioeconomic barriers to timely care, and provider-level implicit bias. Union's public commentary on this topic has been credited by reproductive health organizations with raising broader awareness.

Clinical Context: HRT in the Perimenopause Window

For readers arriving at this page seeking general HRT guidance rather than celebrity context, the clinical picture has shifted considerably over the past two decades.

The Women's Health Initiative (WHI) initially reported increased cardiovascular and breast cancer risks with combined estrogen-progestin therapy in 2002. Subsequent reanalysis, along with the 2017 JAMA 18-year follow-up, established that the risk profile depends heavily on timing. Women who initiate hormone therapy within 10 years of menopause onset or before age 60 ("the timing hypothesis") see net cardiovascular benefit or neutral risk. Those starting later face elevated risk.

Current FDA-approved options for menopausal vasomotor symptoms include:

  • Systemic estrogen (oral estradiol 0.5 to 2 mg/day, transdermal patches delivering 0.025 to 0.1 mg/day)
  • Combined estrogen-progestogen for women with an intact uterus
  • Low-dose vaginal estrogen for genitourinary syndrome of menopause
  • Newer non-hormonal agents such as fezolinetant (a neurokinin 3 receptor antagonist approved in 2023)

Transdermal estrogen delivery avoids first-pass hepatic metabolism, resulting in lower thrombotic risk compared to oral formulations. The Endocrine Society's 2015 clinical practice guideline recommends transdermal estradiol as the preferred route for women with elevated cardiovascular or thromboembolic risk.

What Union's Story Illustrates

Gabrielle Union's public health timeline touches three distinct hormonal intervention categories: fertility stimulation hormones during IVF, the hormonal consequences of adenomyosis, and perimenopause management. Each involves exogenous or dysregulated hormone exposure, and each is commonly misunderstood by the general public.

Her case is particularly instructive because she has been transparent about failure. IVF is often presented through a lens of eventual success stories; Union's account of nearly a decade of attempts, the emotional weight of repeated loss, and the financial reality of multiple cycles offers a corrective. The HealthRX Medical Team views this kind of public disclosure as clinically valuable because it sets realistic expectations for patients entering fertility treatment, especially those with uterine pathology like adenomyosis.

On perimenopause, Union's descriptions of her symptoms align with the most commonly reported vasomotor and neuropsychiatric complaints in the medical literature. Her emphasis on "talking to your doctor early" echoes the clinical consensus that early intervention, whether hormonal or behavioral, produces better quality-of-life outcomes than waiting until symptoms become severe.

Frequently asked questions

›
›
›
›
›

References

  • Vercellini P, et al. "Adenomyosis and reproductive performance after surgery for deep endometriosis." Hum Reprod Update. 2014. PubMed
  • Younes G, Tulandi T. "Effects of adenomyosis on in vitro fertilization treatment outcomes." Fertil Steril. 2017. PubMed
  • Williams CL, et al. "Cancer risk in women who underwent assisted reproduction." BMJ. 2019. PubMed
  • Rossouw JE, et al. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women." JAMA. 2002. PubMed
  • Manson JE, et al. "Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the WHI randomized trials." JAMA. 2017. JAMA
  • "The 2022 hormone therapy position statement of The North American Menopause Society." Menopause. 2022. PubMed
  • Stuenkel CA, et al. "Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline." J Clin Endocrinol Metab. 2015. PubMed
  • Seifer DB, et al. "Racial/ethnic disparities in assisted reproductive technology outcomes." Fertil Steril. 2021. PubMed
  • FDA. "Menopause: Medicines to Help You." FDA.gov